Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Jefferies raised the firm’s price target on Verona Pharma (VRNA) to $45 from $38 and keeps a Buy rating on the shares. Ohtuvayre reported ...

In this article, we will take a look at the 10 Best Pharma Stocks To Buy Right Now.

Canaccord raised the firm’s price target on Verona Pharma (VRNA) to $44 from $37 and keeps a Buy rating on the shares. The firm said they reported Q3 results and noted Ohtuvayre initial sales beat ...

On Friday, Recursion Pharmaceuticals Inc (RXRX) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.17 or 2.45% from the prior close of $6.93. The stock opened ...

Mepsevii sales also jumped ... and justifies the increased price target to $95 based on revisions to their financial model. In other recent news, Ultragenyx Pharmaceutical (NASDAQ:RARE) Inc ...

Prabhudas Lilladher is bullish on Apollo Hospitals Enterprise has recommended buy rating on the stock with a target price of ...

On Friday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.27 which represents a decrease of $-0.03 or -2.31% from the prior close of $1.3. The stock opened at $1.3 and ...

The raised stock price target to $42 per American ... remains optimistic about continued sales growth and the drug's broad prescription base. Verona Pharma's recent financial performance and ...

Most brokerages retained ratings and target prices for Sun Pharmaceutical Industries after its second quarter earnings beat ...

The raised stock price target to $42 per American Depositary ... Despite the net loss for Q3, the company remains optimistic about continued sales growth and the drug's broad prescription base. Verona ...